5‐Aminosalicylic Acid in the Treatment of Inflammatory Bowel Disease
1987; Wiley; Volume: 221; Issue: 3 Linguagem: Inglês
10.1111/j.0954-6820.1987.tb00889.x
ISSN0001-6101
AutoresS Bondesen, Sten Nørby Rasmussen, J Rask-Madsen, Ole Haagen Nielsen, K. Lauritsen, Vibeke Binder, Steen Honoré Hansen, Eigill F. Hvidberg,
Tópico(s)Pharmacological Effects of Natural Compounds
ResumoActa Medica ScandinavicaVolume 221, Issue 3 p. 227-242 Free Access 5-Aminosalicylic Acid in the Treatment of Inflammatory Bowel Disease STIG BONDESEN, STIG BONDESEN Department of Medicine F, Glostrup Hospital, Glostrup, the Department of Medicine I, Aalborg Hospital North, Aalborg, the Department of Medicine B, Bispebjerg Hospital, Copenhagen, the Department of Medicine C, Herlev Hospital, Herlev, the Department of Medicine S, Odense University Hospital, Odense, the Department of Organic Chemistry, Royal Danish School of Pharmacy and the Department of Clinical Pharmacology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorSTEN NØRBY RASMUSSEN, STEN NØRBY RASMUSSEN Department of Medicine F, Glostrup Hospital, Glostrup, the Department of Medicine I, Aalborg Hospital North, Aalborg, the Department of Medicine B, Bispebjerg Hospital, Copenhagen, the Department of Medicine C, Herlev Hospital, Herlev, the Department of Medicine S, Odense University Hospital, Odense, the Department of Organic Chemistry, Royal Danish School of Pharmacy and the Department of Clinical Pharmacology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorJØRGEN RASK-MADSEN, JØRGEN RASK-MADSEN Department of Medicine F, Glostrup Hospital, Glostrup, the Department of Medicine I, Aalborg Hospital North, Aalborg, the Department of Medicine B, Bispebjerg Hospital, Copenhagen, the Department of Medicine C, Herlev Hospital, Herlev, the Department of Medicine S, Odense University Hospital, Odense, the Department of Organic Chemistry, Royal Danish School of Pharmacy and the Department of Clinical Pharmacology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorOLE HAAGEN NIELSEN, OLE HAAGEN NIELSEN Department of Medicine F, Glostrup Hospital, Glostrup, the Department of Medicine I, Aalborg Hospital North, Aalborg, the Department of Medicine B, Bispebjerg Hospital, Copenhagen, the Department of Medicine C, Herlev Hospital, Herlev, the Department of Medicine S, Odense University Hospital, Odense, the Department of Organic Chemistry, Royal Danish School of Pharmacy and the Department of Clinical Pharmacology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorKARSTEN LAURITSEN, KARSTEN LAURITSEN Department of Medicine F, Glostrup Hospital, Glostrup, the Department of Medicine I, Aalborg Hospital North, Aalborg, the Department of Medicine B, Bispebjerg Hospital, Copenhagen, the Department of Medicine C, Herlev Hospital, Herlev, the Department of Medicine S, Odense University Hospital, Odense, the Department of Organic Chemistry, Royal Danish School of Pharmacy and the Department of Clinical Pharmacology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorVIBEKE BINDER, VIBEKE BINDER Department of Medicine F, Glostrup Hospital, Glostrup, the Department of Medicine I, Aalborg Hospital North, Aalborg, the Department of Medicine B, Bispebjerg Hospital, Copenhagen, the Department of Medicine C, Herlev Hospital, Herlev, the Department of Medicine S, Odense University Hospital, Odense, the Department of Organic Chemistry, Royal Danish School of Pharmacy and the Department of Clinical Pharmacology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorSTEEN HONORÉ HANSEN, STEEN HONORÉ HANSEN Department of Medicine F, Glostrup Hospital, Glostrup, the Department of Medicine I, Aalborg Hospital North, Aalborg, the Department of Medicine B, Bispebjerg Hospital, Copenhagen, the Department of Medicine C, Herlev Hospital, Herlev, the Department of Medicine S, Odense University Hospital, Odense, the Department of Organic Chemistry, Royal Danish School of Pharmacy and the Department of Clinical Pharmacology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorEIGILL F. HVIDBERG, Corresponding Author EIGILL F. HVIDBERG MD Department of Medicine F, Glostrup Hospital, Glostrup, the Department of Medicine I, Aalborg Hospital North, Aalborg, the Department of Medicine B, Bispebjerg Hospital, Copenhagen, the Department of Medicine C, Herlev Hospital, Herlev, the Department of Medicine S, Odense University Hospital, Odense, the Department of Organic Chemistry, Royal Danish School of Pharmacy and the Department of Clinical Pharmacology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkDepartment of Clinical Pharmacology, 3124, Rigshospitalet, 9 Blegdamsvej, DK- 2100 Copenhagen Ø, Denmark.Search for more papers by this author STIG BONDESEN, STIG BONDESEN Department of Medicine F, Glostrup Hospital, Glostrup, the Department of Medicine I, Aalborg Hospital North, Aalborg, the Department of Medicine B, Bispebjerg Hospital, Copenhagen, the Department of Medicine C, Herlev Hospital, Herlev, the Department of Medicine S, Odense University Hospital, Odense, the Department of Organic Chemistry, Royal Danish School of Pharmacy and the Department of Clinical Pharmacology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorSTEN NØRBY RASMUSSEN, STEN NØRBY RASMUSSEN Department of Medicine F, Glostrup Hospital, Glostrup, the Department of Medicine I, Aalborg Hospital North, Aalborg, the Department of Medicine B, Bispebjerg Hospital, Copenhagen, the Department of Medicine C, Herlev Hospital, Herlev, the Department of Medicine S, Odense University Hospital, Odense, the Department of Organic Chemistry, Royal Danish School of Pharmacy and the Department of Clinical Pharmacology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorJØRGEN RASK-MADSEN, JØRGEN RASK-MADSEN Department of Medicine F, Glostrup Hospital, Glostrup, the Department of Medicine I, Aalborg Hospital North, Aalborg, the Department of Medicine B, Bispebjerg Hospital, Copenhagen, the Department of Medicine C, Herlev Hospital, Herlev, the Department of Medicine S, Odense University Hospital, Odense, the Department of Organic Chemistry, Royal Danish School of Pharmacy and the Department of Clinical Pharmacology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorOLE HAAGEN NIELSEN, OLE HAAGEN NIELSEN Department of Medicine F, Glostrup Hospital, Glostrup, the Department of Medicine I, Aalborg Hospital North, Aalborg, the Department of Medicine B, Bispebjerg Hospital, Copenhagen, the Department of Medicine C, Herlev Hospital, Herlev, the Department of Medicine S, Odense University Hospital, Odense, the Department of Organic Chemistry, Royal Danish School of Pharmacy and the Department of Clinical Pharmacology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorKARSTEN LAURITSEN, KARSTEN LAURITSEN Department of Medicine F, Glostrup Hospital, Glostrup, the Department of Medicine I, Aalborg Hospital North, Aalborg, the Department of Medicine B, Bispebjerg Hospital, Copenhagen, the Department of Medicine C, Herlev Hospital, Herlev, the Department of Medicine S, Odense University Hospital, Odense, the Department of Organic Chemistry, Royal Danish School of Pharmacy and the Department of Clinical Pharmacology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorVIBEKE BINDER, VIBEKE BINDER Department of Medicine F, Glostrup Hospital, Glostrup, the Department of Medicine I, Aalborg Hospital North, Aalborg, the Department of Medicine B, Bispebjerg Hospital, Copenhagen, the Department of Medicine C, Herlev Hospital, Herlev, the Department of Medicine S, Odense University Hospital, Odense, the Department of Organic Chemistry, Royal Danish School of Pharmacy and the Department of Clinical Pharmacology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorSTEEN HONORÉ HANSEN, STEEN HONORÉ HANSEN Department of Medicine F, Glostrup Hospital, Glostrup, the Department of Medicine I, Aalborg Hospital North, Aalborg, the Department of Medicine B, Bispebjerg Hospital, Copenhagen, the Department of Medicine C, Herlev Hospital, Herlev, the Department of Medicine S, Odense University Hospital, Odense, the Department of Organic Chemistry, Royal Danish School of Pharmacy and the Department of Clinical Pharmacology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorEIGILL F. HVIDBERG, Corresponding Author EIGILL F. HVIDBERG MD Department of Medicine F, Glostrup Hospital, Glostrup, the Department of Medicine I, Aalborg Hospital North, Aalborg, the Department of Medicine B, Bispebjerg Hospital, Copenhagen, the Department of Medicine C, Herlev Hospital, Herlev, the Department of Medicine S, Odense University Hospital, Odense, the Department of Organic Chemistry, Royal Danish School of Pharmacy and the Department of Clinical Pharmacology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkDepartment of Clinical Pharmacology, 3124, Rigshospitalet, 9 Blegdamsvej, DK- 2100 Copenhagen Ø, Denmark.Search for more papers by this author First published: January/December 1987 https://doi.org/10.1111/j.0954-6820.1987.tb00889.xCitations: 35AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abbreviations: 5-ASA 5-aminosalicylic acid HPLC high performance liquid chromatography PG prostaglandin(s) PGI2 prostacyclin TX thromboxane(s) HPETE hydroxyperoxyeicosatetraeonic acid(s) HETE hydroxyeicosatetraenoic acid(s) LT leukotriene(s) References 1 Svartz N. Salazopyrin: A new sulfanilamide preparation. Acta Med Scand 1942; CX, 577– 98. Google Scholar 2 Azad Khan AK, Piris J., Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; 2: 892– 5. CrossrefCASPubMedWeb of Science®Google Scholar 3 van Hees RAM, Bakker JH, van Tongeren JHM. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 1980; 21: 632– 5. CrossrefPubMedWeb of Science®Google Scholar 4 Campieri M., Lanfranchi GA, Bazzocchi G. et al. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 1981; 2: 270– 1. CrossrefPubMedWeb of Science®Google Scholar 5 Molin L., Stendahl O. The effect of sulfasalazine and its active components on human polymorpho-nuclear leukocyte function in relation to ulcerative colitis. Acta Med Scand 1979; 206: 451– 7. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar 6 Sharon P., Ligumsky M., Rachmilewitz D., Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978; 75: 638– 40. CrossrefCASPubMedWeb of Science®Google Scholar 7 Das KM, Eastwood MA, McManus JPA, Sircus W. Adverse reactions during salicylazosulfa-pyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973; 289: 491– 5. CrossrefPubMedWeb of Science®Google Scholar 8 Taffet SL, Das KM. Sulfasalazine: Adverse effects and desensitization. Dig Dis Sci 1983; 28: 833– 42. CrossrefPubMedWeb of Science®Google Scholar 9 Peppercorn MA. Sulfasalazine. Pharmacology, clinical use, toxicity and new drug development. Ann Intern Med 1984; 101: 377– 36. CrossrefCASPubMedWeb of Science®Google Scholar 10 Goldman P. Will there be a next generation of sulfasalazine? Gastroenterology 1982; 83: 1138– 41. CASPubMedWeb of Science®Google Scholar 11 Nemirowski W., Levchenkova I., Romadan I., Veselova L. Ionization constants of aminosalicylic acids. Latvijas PSR Zinatnu akademijas. Vestis, Kimjas ser., Riga 1979; 5: 612– 5. Google Scholar 12 Pieniaszek HJ Jr, Bates TR Colorimetric determination of 5-aminosalicylic acid and its N-ace-tylated metabolite on urine and feces. Res Commun Chem Pathol Pharmacol 1975; 12: 571– 81. CASPubMedWeb of Science®Google Scholar 13 Hansson KA. Determination of free and acetylated 5-aminosalicylic acid in serum and urine after administration of salicylazosulfapyridine. Acta Pharm Suec 1973; 10: 153– 5. CASPubMedWeb of Science®Google Scholar 14 Fischer C., Klotz U. High-performance liquid chromatographic determination of aminosalicylate, sulfapyridine and their metabolites. J Chromatogr 1979; 162: 237– 43. CrossrefCASPubMedWeb of Science®Google Scholar 15 Hansen SH. Assay of 5-aminosalicylate and its acetylated metabolite in biological fluids by high-performance liquid chromatography on dynamically modified silica. J Chromatogr 1981; 226: 504– 9. CrossrefCASPubMedWeb of Science®Google Scholar 16 Fischer C., Maier K., Klotz U. Simplified high-performance liquid chromatographic method for 5-aminosalicylic acid in plasma and urine. J Chromatogr 1981; 225: 498– 503. CrossrefCASPubMedWeb of Science®Google Scholar 17 Dew MJ, Cardwell K., Kidway NS, Evans BK, Rhodes J. 5-aminosalicylic acid in serum and urine after administration by enema to patients with colitis. J Pharm Pharmacol 1983; 35: 323– 4. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar 18 Shaw PN, Sivner AL, Aarons L., Houston JB. A rapid method for the simultaneous determination of the major metabolites of sulphasalazine in plasma. J Chromatogr 1983; 274: 394– 7. CrossrefWeb of Science®Google Scholar 19 van Hogezand RA, van Balen HCJG, van Schaik et al. Determination of sodium azodisalicylate, salazosulphaprydine and their metabolites in serum, urine and faeces by high performance liquid chromatography. J Chromatogr 1984; 305: 470– 6. CrossrefCASPubMedWeb of Science®Google Scholar 20 Kirsner JB, Shorter RG. Recent developments in nonspecific inflammatory bowel disease. N Engl J Med 1982; 306: 775– 85, 837–48. CrossrefCASPubMedWeb of Science®Google Scholar 21 Larsen GL, Henson PM. Mediators of inflammation. Annu Rev Immunol 1983; 1: 335– 59. CrossrefCASPubMedWeb of Science®Google Scholar 22 Samuelsson B., Goldyne M., Granström E., Hamberg M., Hammarström S., Malmsten C. Prostaglan-dins and thromboxanes. Annu Rev Biochem 1978; 47: 997– 1029. CrossrefCASPubMedWeb of Science®Google Scholar 23 Hammerström S. Leukotrienes. Annu Rev Biochem 1983; 52: 355– 77. CrossrefPubMedWeb of Science®Google Scholar 24 Davies P., Bailey PJ, Goldenberg M., Ford-Hutchinson AW. The role of arachidonic acid oxygenation products in pain and inflammation. Annu Rev Immunol 1984; 2: 335– 57. CrossrefCASPubMedWeb of Science®Google Scholar 25 Rask-Madsen J., Bukhave K., Bytzer P., Lauritsen K. Prostaglandins in the gastrointestinal tract. Acta Med Scand 1984; 215 (Suppl 685): 30– 46. Google Scholar 26 Donowitz M. Arachidonic acid metabolites and their role in inflammatory bowel disease. An update requiring addition of a pathway. Gastroenterology 1985; 88: 580– 7. CrossrefCASPubMedWeb of Science®Google Scholar 27 Sharon P., Stenson W. Enhanced synthesis of leukotrienes by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984; 86: 453– 60. CASPubMedWeb of Science®Google Scholar 28 Harris DW, Smith PR, Swan CHJ. Determination of prostaglandin synthetase activity in rectal biopsy material and its significance in colonic disease. Gut 1978; 19: 875– 7. CrossrefCASPubMedWeb of Science®Google Scholar 29 Ligumsky M., Karmeli F., Sharon P., Zor U., Cohen F., Rachmilewitz D. Enhanced trhomboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology 1981; 81: 444– 9. CrossrefCASPubMedWeb of Science®Google Scholar 30 Boughton-Smith NK, Hawkey CJ, Whittle BJK. Biosynthesis of lipoxygenase and cyclo-oxygenase products from [14C] arachidonic acid by human colonic mucosa. Gut 1983; 24: 1176– 82. CrossrefCASPubMedWeb of Science®Google Scholar 31 Bolin T., Heuman R., Sjödahl R., Tageson C. Decreased lysophospholipase and increased phos-pholipase A2 activity in ileal mucosa from patients with Crohn's disease. Digestion 1984; 29: 55– 9. CrossrefCASPubMedWeb of Science®Google Scholar 32 Rampton DS, Sladen GE, Youlten LJF. Rectal mucosal prostaglandin E2 release and its relation to disease activity, electrical potential difference, and treatment in ulcerative colitis. Gut 1980; 21: 591– 6. CrossrefCASPubMedWeb of Science®Google Scholar 33 Lauritsen K., Hansen J., Bytzer P., Bukhave K., Rask-Madsen J. Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 levels determined by equilibrium in vitro dialysis in faeces in patients with ulcerative colitis and healthy controls. Gut 1984; 25: 1271– 8. CrossrefCASPubMedWeb of Science®Google Scholar 34 Gould SR. Prostaglandins, ulcerative colitis, and sulphasalazine. Lancet 1975; 2: 988. CrossrefCASPubMedWeb of Science®Google Scholar 35 Smith PR, Dawson DJ, Swan CH. Prostaglandin synthetase activity in acute ulcerative colitis: effects of treatment with sulphasalazine, codeine phosphate and prednisolone. Gut 1979; 20: 802– 5. CrossrefCASPubMedWeb of Science®Google Scholar 36 Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232– 5. CrossrefCASPubMedGoogle Scholar 37 Gilat T., Ratan J., Rosen P., Peled Y. Prostaglandins and ulcerative colitis. Gastroenterology 1979; 76: 1083. PubMedWeb of Science®Google Scholar 38 Campieri M., Lanfranchi GA, Bazzocchi G. et al. Prostaglandins, indomethacin and ulcerative colitis. Gastroenterology 1980; 78: 193. PubMedWeb of Science®Google Scholar 39 Rampton DS, Sladen GE. Prostaglandin synthesis inhibitors in ulcerative colitis: flurbiprofen compared with conventional treatment. Prostaglandins 1981; 21: 417– 25. CrossrefPubMedWeb of Science®Google Scholar 40 Rampton DS, Sladen GE. Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs. Postgrad Med J 1981; 57: 297– 9. CrossrefPubMedWeb of Science®Google Scholar 41 Rampton DS, McNeil NI, Sarner M. Analgesic ingestion and other factors preceding relapse in ulcerative colitis. Gut 1983; 24: 187– 9. CrossrefPubMedWeb of Science®Google Scholar 42 Hoult JRS, Page H. 5-aminosalicylic acid, a co-factor for colonic prostacyclin synthesis? Lancet 1981; 2: 255. CrossrefCASPubMedWeb of Science®Google Scholar 43 Robert A. Cytoprotection by prostaglandins. Gastroenterology 1979; 77: 761– 7. CrossrefCASPubMedWeb of Science®Google Scholar 44 Robert A., Lancaster C., Hanchar AJ, Nezamis JE. Prostacyclin (PGI2) is cytoprotective for the intestine. Gastroenterology 1980; 78: 1245. Google Scholar 45 Robert A., Nezamis JE, Lancaster C., Hanchar AJ. Prevention through cytoprotection, of clindamycin-induced colitis in hamsters with 16,16-dimethyl PGE2. Gastroenterology 1980; 78: 1245. Google Scholar 46 Lauritsen K., Hansen J., Ryde M., Rask-Madsen J. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology 1984; 86: 1496– 500. CASPubMedWeb of Science®Google Scholar 47 Goldin E., Rachmilewitz D. Prostanoids cytoprotection for maintaining remission in ulcerative colitis: failure of 15-(R)-15 methyl PGE2. Dig Dis Sci 1983; 28: 807– 11. CrossrefCASPubMedWeb of Science®Google Scholar 48 Stenson WF, Lobos E. Sulfasazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest 1982; 69: 494– 7. CrossrefCASPubMedWeb of Science®Google Scholar 49 Siegel MI, McConnell RT, Porter NA, Cuatrecasas P. Arachidonate metabolism via lipoxygenase and 12L-hydroperoxy-5,8,10,14-icosatetraenoic acid peroxidase sensitive to anti-inflammatory drugs. Proc Natl Acad Sci USA 1980; 77: 308– 12. CrossrefCASPubMedWeb of Science®Google Scholar 50 Sircar JC, Schwender CF, Carethers ME. Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol 1983; 32: 170– 2. CrossrefCASPubMedWeb of Science®Google Scholar 51 Allgayer H., Eisenburg J., Paumgartner G. Soybean lipoxygenase inhibition: studies with sulpha-salazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. Eur J Clin Pharmacol 1984; 26: 449– 51. CrossrefCASPubMedWeb of Science®Google Scholar 52 Rask-Madsen J., Bukhave K. The difficulties of establishing the pathophysiological role of prostaglandins in secretion. In: E. Skadhauge, K. Heintze, eds. Intestinal absorption and secretion. Lancaster: MTP Press, 1984: 453– 68. Google Scholar 53 Nielsen OH, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol 1983; 16: 738– 40. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar 54 Fischer C., Maier K., Klotz U. Specific measurement of 5-aminosalicylic acid and its acetylated metabolites in human bile. Br J Clin Pharmacol 1983; 15: 273– 4. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar 55 Klotz U., Maier KE, Fischer C., Bauer KH. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Arzneim-Forsch/Drug Res 1985; 35: 636– 9. CASPubMedWeb of Science®Google Scholar 56 Fischer C., Maier K., Stumpf E., von Gaisberg U., Klotz U. Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine in man. Eur J Clin Pharmacol 1983; 25: 511– 5. CrossrefPubMedWeb of Science®Google Scholar 57 Meese CO, Fischer C., Klotz U. Is N-acetylation of 5-aminosalicylic acid reversible in man? Br J Clin Pharmacol 1984; 18: 612– 5. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar 58 Rasmussen SN, Bondesen S., Hvidberg EF et al. 5-Aminosalicylic acid in a slow release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology 1982; 83: 1062– 70. PubMedWeb of Science®Google Scholar 59 Pieniaszek HJ Jr, Bates TR Capacity-limited gut wall metabolism of 5-aminosalicylic acid, a therapeutically active metabolite of sulfasalazine, in rats. J Pharm Sci 1979; 68: 1323– 5. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar 60 Bondesen S., Nielsen OH, Jacobsen O. et al. 5-Aminosalicylic acid enemas in patients with active ulcerative colitis; Influence of acidity on the kinetic pattern. Scand J Gastroenterol 1984; 19: 677– 82. CrossrefCASPubMedWeb of Science®Google Scholar 61 Azad Khan AK, Truelove SC. Placental and mammary transfer of sulphasalazine. Br Med J 1979; 2: 1553. CrossrefGoogle Scholar 62 Hvidberg EF, Rasmussen SN, Hansen SH, Bondesen S. 5-aminosalicylic acid (5-ASA) in amniotic fluid, cord and maternal plasma, and breast milk during sulfasalazine treatment (Abstract). In: Abstract book, Iuphar 9th International Congress of Pharmacology. London: 1984; no. 2205. Google Scholar 63 Calder IC, Williams PJ, Woods RA et al. Nephrotoxicity and molecular structure. Xenobiotica 1975; 5: 303– 7. CrossrefCASPubMedWeb of Science®Google Scholar 64 Calder IC, Funder CC, Green CR, Ham KN, Tange JD. Nephrotoxic lesions from 5-aminosalicylic acid. Br Med J 1972; 1: 152– 4. CrossrefCASPubMedWeb of Science®Google Scholar 65 Diener U., Tuczek HV, Fischer C., Maier K., Klotz U. Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. Naunyn Schmiedebergs Arch Pharmacol 1984; 326: 278– 82. CrossrefCASPubMedWeb of Science®Google Scholar 66 Dew MJ, Harries AD, Evens BK, Rhodes J. Treatment of ulcerative colitis with oral 5-aminosalicylic acid in patients unable to take sulphasalazine. Lancet 1983; 2: 801. CrossrefPubMedWeb of Science®Google Scholar 67 Morain CO, Smethurst P., Levi AJ. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut 1984; 25: 1078– 84. CrossrefCASPubMedWeb of Science®Google Scholar 68 Cann PA, Holdworth CD. Reversal of male infertility on changing treatment from sulphasalazine to 5-aminosalicylic acid. Lancet 1984; 1: 1119. CrossrefCASPubMedWeb of Science®Google Scholar 69 Shaffer JL, Kershaw A., Berrisford MH. Sulphasalazine-induced infertility reversed on transfer to 5-aminosalicylic acid. Lancet 1984; 1: 1240. CrossrefCASPubMedWeb of Science®Google Scholar 70 Lanfranchi GA, Campieri M., Brignola C. et al. 2 years experience with high dosage 5-ASA enemas (Abstract). In: Abstract book, 12th International Congress of Gastroenterology and 5th International Congress of Gastrointestinal Endoscopy. Lisboa: 1984; 514. Google Scholar 71 Klotz U., Maier K., Fischer C., Heinkel K. Therapeutics efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohns disease. N Engl J Med 1980; 303: 1499– 502. CrossrefPubMedWeb of Science®Google Scholar 72 Willoughby CP, Campieri M., Lanfranchi G., Truelove SC, Jewell DP. 5-Aminosalicylic acid (Pen-tasa) in enema form for the treatment of active ulcerative colitis. Ital J Gastroenterol 1986; 18: 15– 7. Web of Science®Google Scholar 73 A Danish 5-ASA study group Topical 5-aminosalicylic acid versus prednisolone in ulcerative proc-tosigmoiditis. Dig Dis Sci. (In press.). Google Scholar 74 Janssens J., Geboes K., Delanote C., Vantrappen G. 5-Aminosalicylic acid (5-ASA) enemas are effective in patients with resistant ulcerative rectosigmoiditis. Gastroenterology 1983; 84: 1198. Google Scholar 75 Friedman LS, Richter JM, Kirkham SE, DeMonaco H., May RJ. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis. A randomized controlled trial. Gastroenterology 1985; 88:part 2: 1388. Google Scholar 76 Barber GB, Lee DE, Antonioli DA, Peppercorn MA. Refractory distal ulcerative colitis responsive to 5-aminosalicylate enemas. Am J Gastroenterol 1985; 80: 612– 4. CASPubMedWeb of Science®Google Scholar 77 Campierri M., Lanfranchi GA, Brignola C., Bazzocchi G., Minguzzi MR, Calari MT. 5-Aminosalicylic acid as rectal enema in ulcerative colitis patients unable to take sulphasalazine. Lancet 1984; 1: 403. CrossrefGoogle Scholar 78 Willoughby CP, Piris J., Truelove SC. The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis. Scand J Gastroenterol 1980; 15: 715– 9. CrossrefCASPubMedWeb of Science®Google Scholar 79 Binder V., Halskov S., Hvidberg EF et al. A controlled study of 5-acet-aminosalicylic acid as enema in ulcerative colitis. Scand J Gastroenterol 1981; 16: 1122. Google Scholar 80 van Hees PAM, Tuinte JHM, van Rossum JM, van Tongeren JHM. Influence of intestinal transit time on azoreduction of salicylazosulphapyridine (Salazopyrin). Gut 1979; 20: 300– 4. CrossrefCASPubMedWeb of Science®Google Scholar 81 Peppercorn MA, Goldman P. Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology 1973; 64: 240– 5. CrossrefCASPubMedWeb of Science®Google Scholar 82 Das KM, Eastwood MA, McManus JPA, Sircus W. The role of the colon in the metabolism of salicylazosulphapyridine. Scand J Gastroenterol 1974; 9: 137– 41. CASPubMedWeb of Science®Google Scholar 83 Baron JH, Conell AM, Lennard-Jones JE, Avery Jones F. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962; 1: 1094– 6. CrossrefCASPubMedWeb of Science®Google Scholar 84 Dick AP, Grayson MJ, Carpenter RG, Petrie A. Controlled trial of sulphasalazine in treatment of ulcerative colitis. Gut 1964; 5: 437– 42. CrossrefPubMedWeb of Science®Google Scholar 85 Misiewicz JJ, Lennard-Jones JE, Connell AM, Baron JH, Avery Jones F Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965; 1: 185– 8. CrossrefWeb of Science®Google Scholar 86 Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin). Gut 1973; 14: 923– 6. CrossrefCASPubMedWeb of Science®Google Scholar 87 Summers RW, Switz DM, Sessions JT et al. National Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology 1979; 77: 847– 69. CrossrefCASPubMedWeb of Science®Google Scholar 88 Chan RP, Pope DJ, Gilbert AP, Sacra PJ, Baron JH, Lennard-Jones JE. Studies of two novel sulfasalazine analogs, Ipsalazide and Balsalazide. Dig Dis Sci 1983; 28: 609– 15. CrossrefCASPubMedWeb of Science®Google Scholar 89 Sandberg-Gertzén H., Ryde M., Järnerot G. Absorption and excretion of a single 1 g dose of azodisal sodium in subjects with ileostomy. Scand J Gastroenterol 1983; 18: 107– 11. CrossrefCASPubMedWeb of Science®Google Scholar 90 Sandberg-Gertzén H., Ryde M., Järnerot G. Absorption and excretion of azodisal sodium and its metabolites in man after rectal administration of a single 2 g dose. Scand J Gastroenterol 1983; 18: 571– 5. CrossrefPubMedWeb of Science®Google Scholar 91 Willoughby CP, Aronson JR, Agback H., Bodin NO, Truelove SC. Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut 1982; 23: 1081– 7. CrossrefCASPubMedWeb of Science®Google Scholar 92 Selby WS, Barr GD, Ireland A., Mason CH, Jewell DP. Olsalazine in active ulcerative colitis. DMJ 1985; 291: 1373– 5. PubMedWeb of Science®Google Scholar 93 Sandberg-Gertzén H., Järnerot G., Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. Gastroenterology 1986; 90: 1024– 30. CrossrefPubMedWeb of Science®Google Scholar 94 Brown TP, McGarraugh GV, Parkinson JM. A polymeric drug for the treatment of inflammatory bowel disease. J Med Chem 1983; 26: 1300– 7. CrossrefCASPubMedWeb of Science®Google Scholar 95 Lashner BA, Savina PM, Garetto M. et al. Release of 5-aminosalicylic acid (5-ASA) from BW73Y: in vitro and in vivo studies in humans. Gastroenterology 1984; 86: 1154. Web of Science®Google Scholar 96 Garetto M., Riddell RH, Winans CS. Treatment of chronic ulcerative colitis with poly-ASA: A new non-absorbable carrier for release of 5-aminosalicylate in the colon. Gastroenterology 1983; 84: 1162. Google Scholar 97 Bartalsky A. Salicylazobenzoic acid in ulcerative colitis. Lancet 1982; 1: 960. CrossrefCASPubMedWeb of Science®Google Scholar 98 Dew MJ, Hughes PJ, Lee MG, Evans BK, Rhodes J. An oral preparation to release drugs in the human colon. Br J Clin Pharmacol 1982; 14: 405– 8. Wiley Online LibraryPubMedWeb of Science®Google Scholar 99 Dew MJ, Ryder REJ, Evans BK, Rhodes J. Colonic release of 5-aminosalicylic acid from an oral preparation in active ulcerative colitis. Br J Clin Pharmacol 1983; 16: 185– 7. Wiley Online LibraryPubMedWeb of Science®Google Scholar 100 Dew MJ, Ebden P., Kidwai NS, Lee G., Evans BK, Rhodes J. Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-aminosalicylic acid in normal subjects and patients with ulcerative colitis. Br J Clin Pharmacol 1984; 17: 474– 6. Wiley Online LibraryPubMedWeb of Science®Google Scholar 101 Dew MJ, Harries AD, Evans N., Evans BK, Rhodes J. Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. Br Med J 1983; 287: 23– 4. CrossrefCASPubMedWeb of Science®Google Scholar 102 Bondesen S., Tage-Jensen U., Jacobsen O., Hansen SH, Rasmussen SN, Hvidberg EF. 5-Amino-salicylic acid in patients with ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and pentasa. Eur J Clin Pharmacol 1986; 31: 23– 6. CrossrefCASPubMedWeb of Science®Google Scholar 103 Rasmussen SN, Binder V., Maier K. et al. Treatment of Crohn's disease with peroral 5-aminosalicylic acid. Gastroenterolotgy 1983; 85: 1350– 3. PubMedWeb of Science®Google Scholar 104 Saverymuttu SH, Gupta S., Keshavarzian A., Donovan B., Hodgson HJF. Effect of slow release a 5-aminosalicylic acid preparation on disease activity in Crohn's disease. Digestion 1986; 33: 89– 91. CrossrefPubMedWeb of Science®Google Scholar 105 Campieri M., Lanfranchi GA, Bertoni F. et al. A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. Digestion 1984; 29: 204– 8. CrossrefPubMedWeb of Science®Google Scholar 106 Selby WS, Bennett MK, Jewell DP. Topical treatment of distal ulcerative colitis with 4-aminosalicylic acid enemas. Digestion 1984; 29: 231– 4. CrossrefPubMedWeb of Science®Google Scholar 107 Ursing B., Aim T., Bárány F. et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: The Cooperative Crohn's Disease Study in Sweden. II Result. Gastroenterology 1982; 83: 550– 62. PubMedWeb of Science®Google Scholar Citing Literature Volume221, Issue3January/December 1987Pages 227-242 ReferencesRelatedInformation
Referência(s)